Long-Term Immunological Memory of SARS-CoV-2 Is Present in Patients with Primary Antibody Deficiencies for up to a Year after Vaccination
Author:
Lucane Zane1ORCID, Slisere Baiba12, Ozola Lota3, Rots Dmitrijs13, Papirte Sindija1, Vilne Baiba1ORCID, Gailite Linda1ORCID, Kurjane Natalja123
Affiliation:
1. Riga Stradins University, Riga LV-1007, Latvia 2. Pauls Stradins Clinical University Hospital, Riga LV-1007, Latvia 3. Children’s Clinical University Hospital, Riga LV-1007, Latvia
Abstract
Some studies have found increased coronavirus disease-19 (COVID-19)-related morbidity and mortality in patients with primary antibody deficiencies. Immunization against COVID-19 may, therefore, be particularly important in these patients. However, the durability of the immune response remains unclear in such patients. In this study, we evaluated the cellular and humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in a cross-sectional study of 32 patients with primary antibody deficiency (n = 17 with common variable immunodeficiency (CVID) and n = 15 with selective IgA deficiency) and 15 healthy controls. Serological and cellular responses were determined using enzyme-linked immunosorbent assay and interferon-gamma release assays. The subsets of B and T lymphocytes were measured using flow cytometry. Of the 32 patients, 28 had completed the vaccination regimen with a median time after vaccination of 173 days (IQR = 142): 27 patients showed a positive spike-peptide-specific antibody response, and 26 patients showed a positive spike-peptide-specific T-cell response. The median level of antibody response in CVID patients (5.47 ratio (IQR = 4.08)) was lower compared to healthy controls (9.43 ratio (IQR = 2.13)). No difference in anti-spike T-cell response was found between the groups. The results of this study indicate that markers of the sustained SARS-CoV-2 spike-specific immune response are detectable several months after vaccination in patients with primary antibody deficiencies comparable to controls.
Funder
Latvian Council of Science
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference56 articles.
1. Gathmann, B., Grimbacher, B., Beauté, J., Dudoit, Y., Mahlaoui, N., Fischer, A., Knerr, V., Kindle, G., Micol, R., and Benslama, L. (2009). Proceedings of the Clinical and Experimental Immunology, Oxford University Press. 2. Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management;Yazdani;Scand. J. Immunol.,2017 3. Predominantly Antibody-Deficient Patients With Non-Infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells;Edwards;Front. Immunol.,2019 4. Outbreak of Pneumonia of Unknown Etiology in Wuhan, China: The Mystery and the Miracle;Lu;J. Med. Virol.,2020 5. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin;Zhou;Nature,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|